APYX · Apyx Medical Corp
Market Cap
$105.31M
Shares
42.12M
Volume · Oct 5
68.39K
Avg daily vol (3M)
124.47K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.55
Open$2.51
Day$2.50–2.60
52W close$2.09–4.86
Avg vol 30d157K
Short int218K · 0.5% float · 2.5d
Short vol58%
Last earningsAug 6, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 4 wks
filed Aug 6, 2026
call held May 7, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$58.41M
Trailing 12 months
Net income (TTM)
−$8.61M
Trailing 12 months
Revenue growth YoY
+22.1%
Year over year
Operating margin
-6.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-10.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.1%
Year over year · more shares
Price change (1Y)
+22.0%
Trailing year
Short interest
0.5%
Latest settlement · 2.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−31%
below
Price vs 50-day avg
−20%
below
RSI (14)
35
neutral
MACD trend
Negative
52-week position
17%
mid-range
Momentum
relative strength
1-month return
−17%
trailing
6-month return
−34%
trailing
YTD return
−27%
this year
Relative strength
−46%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.52% of float · ▲ +6.3% MoM · 2.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
67 holders — near 3-yr high, broad support
Squeeze score
36
low risk · 0–100
Fundamentals
Revenue growth
+10%
Y/Y
Gross margin
63%
expanding
EPS growth
+19%
Y/Y
Free cash flow
$-9.1M
Balance sheet
$5.8M
net debt
Quant / Vol
risk profile
Volatility
80%
annualized · 1-yr
Max drawdown
−50%
past year
ATR
7.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
year ending December 31, 2026
Total revenue
Initiated
$59M – $60M
prior FY $52.84M
midpoint +12.6% Y/Y
Surgical Aesthetics revenue
Initiated
$54M – $55M
OEM revenue
Initiated
$5M
year ended December 31, 2026
Operating expenses
Initiated
up to $45M
Guided vs delivered
· last 5 settled
Total revenue
year ending December 31, 2024
guided $50.6M – $52.1M
$48.1M
Miss −6.3%
Total revenue
year ending December 31, 2023
guided $53M – $54M
$52.35M
Miss −2.2%
Total revenue
year ending December 31, 2022
guided $44.8M – $47.9M
$44.51M
Miss −4.0%
Total revenue
12 months ending December 31, 2021
guided $44M – $45M
$48.52M
Beat +9.0%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−31%
Bearish
Price vs 50-day avg
−20%
Bearish
RSI (14)
35
Neutral
MACD trend
Negative
Bearish
52-week position
17%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.52% of float · ▲ +6.3% MoM · 2.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
67 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $3 · 17%
Range high $5
vs 200-day avg -31%
vs 50-day avg -20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$1.03M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA loss non-GAAP | $0.7M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
APYX
this stock
Apyx Medical Corp
|
$105.31M | -27.1% | +9.9% | — | 0.5% |
|
ABT
Abbott Laboratories
|
$174.90B | -22.2% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.1% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -55.3% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| APYX | -13.9% | -16.7% | -34.3% | +4.1% | -27.1% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -13.6% | -16.2% | -46.5% | +3.2% | -40.0% |